达格列净治疗后eGFR初始下降在HFmrEF/HFpEF中的意义:DELIVER试验预设二次分析
该预设分析基于DELIVER随机对照试验,纳入5788例射血分数>40%的心衰患者,比较达格列净10mg/日与安慰剂对eGFR初始下降的影响及其与临床结局的关联。结果显示达格列净组eGFR初始下降更常见,但初始eGFR下降>10%仅与安慰剂组心血管事件风险升高相关,而在达格列净组无此关联,且不增加肾脏不良结局风险。
要点
- 达格列净组40%患者出现eGFR下降>10%,高于安慰剂组的25%。
- 达格列净治疗下eGFR初始下降>10%不增加后续心血管或肾脏事件风险。
核心结论
- 在HFmrEF或HFpEF患者中,达格列净相关eGFR初始下降常见,但与后续心血管或肾脏事件风险无关。
研究设计与样本
- DELIVER随机临床试验的预设二次分析,纳入5788例EF>40%且eGFR≥25的心衰患者,比较达格列净10mg/日与安慰剂。
主要发现
- eGFR从基线至1个月中位变化:安慰剂-1(-6至5),达格列净-4(-9至1),差异-3,P<.001。
- eGFR下降>10%者:达格列净组1144/2892(40%),安慰剂组737/2896(25%),OR 1.9(95%CI 1.7-2.1),P<.001。
- 在安慰剂组,eGFR下降>10%与主要心血管结局风险升高相关(aHR 1.33,95%CI 1.10-1.62);达格列净组无此关联(aHR 0.90,95%CI 0.74-1.09;交互P=.01)。
- 达格列净组eGFR下降>10%与后续肾脏复合结局无关(aHR 0.94,95%CI 0.49-1.82)。
临床怎么用
- SGLT2i治疗初期出现的eGFR下降不应作为中断或停药的理由。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: An initial decline in estimated glomerular filtration rate (eGFR) is expected after initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed across patients with diabetes, chronic kidney disease, and heart failure. OBJECTIVE: To examine the implications of initial changes in eGFR among patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis of the results of the DELIVER randomized clinical trial, which was an international multicenter study of patients with EF greater than 40% and eGFR greater than or equal to 25. The DELIVER trial took place from August 2018 to March 2022. Data for the current prespecified study were analyzed from February to October 2023. INTERVENTION: Dapagliflozin, 10 mg per day, or placebo. MAIN OUTCOMES AND MEASURES: In this prespecified analysis, the frequency of an initial eGFR decline (baseline to month 1) was compared between dapagliflozin and placebo. Cox models adjusted for baseline eGFR and established prognostic factors were fit to estimate the association of an initial eGFR decline with cardiovascular (cardiovascular death or heart failure event) and kidney (≥50% eGFR decline, eGFR<15 or dialysis, death from kidney causes) outcomes, landmarked at month 1, stratified by diabetes. RESULTS: Study data from 5788 participants (mean [SD] age, 72 [10] years; 3253 male [56%]) were analyzed. The median (IQR) change in eGFR level from baseline to month 1 was -1 (-6 to 5) with placebo and -4 (-9 to 1) with dapagliflozin (difference, -3; P < .001). A higher proportion of patients assigned to dapagliflozin developed an initial eGFR decline greater than 10% vs placebo (1144 of 2892 [40%] vs 737 of 2896 [25%]; odds ratio, 1.9; 95% CI, 1.7-2.1; P difference <.001). An initial eGFR decline of greater than 10% (vs ≤10%) was associated with a higher risk of the primary cardiovascular outcome among those randomized to placebo (adjusted hazard ratio [aHR], 1.33; 95% CI, 1.10-1.62) but not among those randomized to dapagliflozin (aHR, 0.90; 95% CI, 0.74-1.09; P for interaction = .01). Similar associations were observed when alternative thresholds of initial eGFR decline were considered and when analyzed as a continuous measure. An initial eGFR decline of greater than 10% was not associated with adverse subsequent kidney composite outcomes in dapagliflozin-treated patients (aHR, 0.94; 95% CI, 0.49-1.82). CONCLUSIONS AND RELEVANCE: Among patients with HFmrEF or HFpEF treated with dapagliflozin, an initial eGFR decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that SGLT2is should not be interrupted or discontinued in response to an initial eGFR decline. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.
引用
- Mc Causland, Claggett, Vaduganathan, et al. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 37952176. doi:10.1001/jamacardio.2023.4664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。